Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compare the Pharmacokinetics, Safety, Tolerance and Immunogenicity of Single Doses of IBI310 and Ipilimumab in Healthy Male Subjects: a Randomized Double-blind Parallel Controlled Phase I Clinical Study

Next Previous
X
Search
Trial Profile

Compare the Pharmacokinetics, Safety, Tolerance and Immunogenicity of Single Doses of IBI310 and Ipilimumab in Healthy Male Subjects: a Randomized Double-blind Parallel Controlled Phase I Clinical Study

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Acral lentiginous melanoma; Cervical cancer; Colorectal cancer; Gastric cancer; Liver cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Innovent Biologics

    • Most Recent Events

    • 13 Sep 2022 Planned primary completion date changed from 5 Feb 2022 to 1 Sep 2022.
    • 13 Sep 2022 Status changed from recruiting to active, no longer recruiting.
    • 21 Jun 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top